132 related articles for article (PubMed ID: 30326767)
1. Are antioxidant parameters in serum altered in patients with relapsing-remitting multiple sclerosis treated with II-line immunomodulatory therapy?
Adamczyk B; Koziarska D; Kasperczyk S; Adamczyk-Sowa M
Free Radic Res; 2018 Oct; 52(10):1083-1093. PubMed ID: 30326767
[TBL] [Abstract][Full Text] [Related]
2. The Evaluation of Oxidative Stress Parameters in Serum Patients with Relapsing-Remitting Multiple Sclerosis Treated with II-Line Immunomodulatory Therapy.
Adamczyk B; Wawrzyniak S; Kasperczyk S; Adamczyk-Sowa M
Oxid Med Cell Longev; 2017; 2017():9625806. PubMed ID: 29138683
[TBL] [Abstract][Full Text] [Related]
3. Previous treatment influences fingolimod efficacy in relapsing-remitting multiple sclerosis: results from an observational study.
Baldi E; Guareschi A; Vitetta F; Senesi C; Curti E; Montepietra S; Simone AM; Immovilli P; Caniatti L; Tola MR; Pesci I; Montanari E; Sola P; Granella F; Motti L; Ferraro D
Curr Med Res Opin; 2014 Sep; 30(9):1849-55. PubMed ID: 24831186
[TBL] [Abstract][Full Text] [Related]
4. Are natalizumab and fingolimod analogous second-line options for the treatment of relapsing-remitting multiple sclerosis? A clinical practice observational study.
Gajofatto A; Bianchi MR; Deotto L; Benedetti MD
Eur Neurol; 2014; 72(3-4):173-80. PubMed ID: 25226868
[TBL] [Abstract][Full Text] [Related]
5. Teriflunomide for multiple sclerosis.
He D; Xu Z; Dong S; Zhang H; Zhou H; Wang L; Zhang S
Cochrane Database Syst Rev; 2012 Dec; 12():CD009882. PubMed ID: 23235682
[TBL] [Abstract][Full Text] [Related]
6. Natalizumab vs interferon beta 1a in relapsing-remitting multiple sclerosis: a head-to-head retrospective study.
Lanzillo R; Quarantelli M; Bonavita S; Ventrella G; Lus G; Vacca G; Prinster A; Orefice G; Tedeschi G; Brescia Morra V
Acta Neurol Scand; 2012 Nov; 126(5):306-14. PubMed ID: 22107083
[TBL] [Abstract][Full Text] [Related]
7. Elevated melatonin levels in natalizumab-treated female patients with relapsing-remitting multiple sclerosis: relationship to oxidative stress.
Bahamonde C; Conde C; Agüera E; Lillo R; Luque E; Gascón F; Feijóo M; Cruz AH; Sánchez-López F; Túnez I
Eur J Pharmacol; 2014 May; 730():26-30. PubMed ID: 24582759
[TBL] [Abstract][Full Text] [Related]
8. Natalizumab versus fingolimod in patients with relapsing-remitting multiple sclerosis non-responding to first-line injectable therapies.
Baroncini D; Ghezzi A; Annovazzi PO; Colombo B; Martinelli V; Minonzio G; Moiola L; Rodegher M; Zaffaroni M; Comi G
Mult Scler; 2016 Sep; 22(10):1315-26. PubMed ID: 27230789
[TBL] [Abstract][Full Text] [Related]
9. Cytokines and disability in interferon-β-1b treated and untreated women with multiple sclerosis.
Trenova AG; Slavov GS; Manova MG; Kostadinova II
Arch Med Res; 2014 Aug; 45(6):495-500. PubMed ID: 25130430
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of natalizumab in second line therapy of relapsing-remitting multiple sclerosis: results from a multi-center study in German speaking countries.
Putzki N; Yaldizli O; Mäurer M; Cursiefen S; Kuckert S; Klawe C; Maschke M; Tettenborn B; Limmroth V
Eur J Neurol; 2010 Jan; 17(1):31-7. PubMed ID: 19614963
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of fingolimod and interferon beta-1b on cognitive, MRI, and clinical outcomes in relapsing-remitting multiple sclerosis: an 18-month, open-label, rater-blinded, randomised, multicentre study (the GOLDEN study).
Comi G; Patti F; Rocca MA; Mattioli FC; Amato MP; Gallo P; Centonze D; Pozzilli C; Saccà F; Bergh FT; Bartezaghi M; Turrini R; Filippi M;
J Neurol; 2017 Dec; 264(12):2436-2449. PubMed ID: 29063244
[TBL] [Abstract][Full Text] [Related]
12. Systematic literature review and network meta-analysis in highly active relapsing-remitting multiple sclerosis and rapidly evolving severe multiple sclerosis.
Huisman E; Papadimitropoulou K; Jarrett J; Bending M; Firth Z; Allen F; Adlard N
BMJ Open; 2017 Mar; 7(3):e013430. PubMed ID: 28283486
[TBL] [Abstract][Full Text] [Related]
13. [Treatment of relapsing-remitting multiple sclerosis with fingolimod in routine clinical practice].
Alcala-Vicente C; Perez-Miralles FC; Gascon-Gimenez F; Bosca-Blasco I; Navarre-Gimeno A; Coret-Ferrer F; Casanova-Estruch B
Rev Neurol; 2017 May; 64(10):445-453. PubMed ID: 28497440
[TBL] [Abstract][Full Text] [Related]
14. Natalizumab strongly suppresses cortical pathology in relapsing-remitting multiple sclerosis.
Rinaldi F; Calabrese M; Seppi D; Puthenparampil M; Perini P; Gallo P
Mult Scler; 2012 Dec; 18(12):1760-7. PubMed ID: 22570359
[TBL] [Abstract][Full Text] [Related]
15. Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study.
Khatri B; Barkhof F; Comi G; Hartung HP; Kappos L; Montalban X; Pelletier J; Stites T; Wu S; Holdbrook F; Zhang-Auberson L; Francis G; Cohen JA;
Lancet Neurol; 2011 Jun; 10(6):520-9. PubMed ID: 21571593
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of serum human epididymis protein 4 in patients with relapsing-remitting multiple sclerosis.
Adamczyk B; Partyka R; Adamczyk-Sowa M; Wierzbicki K; Sowa P; Kokocińska D
Adv Clin Exp Med; 2020 Aug; 29(8):943-948. PubMed ID: 32790249
[TBL] [Abstract][Full Text] [Related]
17. Severe disease reactivation in four patients with relapsing-remitting multiple sclerosis after fingolimod cessation.
Berger B; Baumgartner A; Rauer S; Mader I; Luetzen N; Farenkopf U; Stich O
J Neuroimmunol; 2015 May; 282():118-22. PubMed ID: 25903738
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of fingolimod versus interferon beta-1a for relapsing remitting multiple sclerosis in the United States.
Lee S; Baxter DC; Limone B; Roberts MS; Coleman CI
J Med Econ; 2012; 15(6):1088-96. PubMed ID: 22583065
[TBL] [Abstract][Full Text] [Related]
19. Escalation to natalizumab or switching among immunomodulators in relapsing multiple sclerosis.
Prosperini L; Giannì C; Leonardi L; De Giglio L; Borriello G; Galgani S; Pozzilli C; Gasperini C
Mult Scler; 2012 Jan; 18(1):64-71. PubMed ID: 21828195
[TBL] [Abstract][Full Text] [Related]
20. Laquinimod for multiple sclerosis.
He D; Han K; Gao X; Dong S; Chu L; Feng Z; Wu S
Cochrane Database Syst Rev; 2013 Aug; (8):CD010475. PubMed ID: 23922214
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
